Disease: Large B-cell lymphoma
Indication: Patients up to 25 years of age with B-cell precursor acute lymphoblasticleukemia (ALL) that is refractory or in second or later relapse.
Company: Novartis Pharmaceuticals
Methods: Patient’s T cells are modified to recognize CD19 on B cells, expanded, and reintroduced to the patient to combat Large B-cell Lymphoma.
Current Phase: FDA Approved
Subscribe to our newsletter to keep up to date with all the latest news about AGT!